SilverCrest Metals
SILV
Collegium Pharmaceutical
COLL
Cars.com
CARS
Halozyme Therapeutics
HALO
Hutchmed (China)
HCM
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Current assets | ||||||||||
Cash, cash equivalents and short term investments | 52.25%100.88M | -12.86%68.13M | -4.35%69.01M | 27.60%91.83M | 27.60%91.83M | -34.86%66.26M | -75.77%78.19M | -79.35%72.14M | -68.70%71.96M | -68.70%71.96M |
-Cash and cash equivalents | 72.60%66.7M | -4.89%39.46M | 21.33%39.87M | 92.45%57.32M | 92.45%57.32M | -38.18%38.65M | -84.96%41.48M | -88.77%32.86M | -74.36%29.79M | -74.36%29.79M |
-Short-term investments | 23.76%34.18M | -21.87%28.67M | -25.82%29.14M | -18.19%34.51M | -18.19%34.51M | -29.58%27.62M | -21.80%36.7M | -31.04%39.29M | -62.92%42.18M | -62.92%42.18M |
Receivables | 12.45%88.37M | 13.84%85.94M | 18.00%82.77M | 20.51%81.07M | 20.51%81.07M | 20.71%78.58M | 26.54%75.49M | 21.07%70.15M | 21.52%67.27M | 21.52%67.27M |
-Notes receivable | 12.45%88.37M | 13.84%85.94M | 18.00%82.77M | 20.51%81.07M | 20.51%81.07M | 20.71%78.58M | 26.54%75.49M | 21.07%70.15M | 21.52%67.27M | 21.52%67.27M |
Inventory | -19.28%31.44M | -47.61%31.99M | -66.93%29.22M | -62.77%32.94M | -62.77%32.94M | -31.91%38.95M | 32.75%61.05M | 157.65%88.34M | 273.93%88.47M | 273.93%88.47M |
Total current assets | 20.07%220.69M | -13.35%186.06M | -21.52%181M | -9.60%205.84M | -9.60%205.84M | -17.96%183.8M | -49.88%214.73M | -47.78%230.63M | -26.30%227.7M | -26.30%227.7M |
Non current assets | ||||||||||
Net PPE | 9.11%30.76M | 46.49%30.06M | 46.74%29.56M | 11.34%5.93M | 11.34%5.93M | 8.78%28.19M | -19.14%20.52M | -18.86%20.14M | 7.12%5.32M | 7.12%5.32M |
-Gross PPE | 9.11%30.76M | 8.35%30.06M | 8.49%29.56M | 9.00%29.13M | 9.00%29.13M | 8.78%28.19M | 9.32%27.74M | 9.75%27.25M | 9.35%26.72M | 9.35%26.72M |
-Accumulated depreciation | ---- | ---- | ---- | -8.42%-23.2M | -8.42%-23.2M | ---- | ---7.22M | ---7.1M | -9.91%-21.4M | -9.91%-21.4M |
Investments and advances | 14.53%26.72M | 13.01%26.21M | 4.84%24.92M | 34.90%24.85M | 34.90%24.85M | 116.88%23.33M | 110.66%23.19M | 162.52%23.77M | 106.13%18.42M | 106.13%18.42M |
Other non current assets | 20.42%17.14M | 3.01%15.49M | -6.50%14.51M | -41.39%11.73M | -41.39%11.73M | -31.01%14.23M | -21.07%15.03M | -14.03%15.52M | 16.78%20.01M | 16.78%20.01M |
Total non current assets | 5.93%1.28B | 6.45%1.26B | 8.40%1.24B | 9.39%1.22B | 9.39%1.22B | 15.94%1.21B | 18.52%1.18B | 17.23%1.14B | 16.12%1.12B | 16.12%1.12B |
Total assets | 7.80%1.5B | 3.40%1.44B | 3.36%1.42B | 6.17%1.43B | 6.17%1.43B | 9.94%1.39B | -2.07%1.39B | -3.08%1.37B | 5.81%1.34B | 5.81%1.34B |
Liabilities | ||||||||||
Current liabilities | ||||||||||
Payables | -4.12%5.73M | -19.66%5.39M | -4.42%5.75M | -4.40%6.11M | -4.40%6.11M | -11.67%5.98M | 46.63%6.7M | 37.92%6.02M | 49.44%6.39M | 49.44%6.39M |
-accounts payable | -4.12%5.73M | -19.66%5.39M | -4.42%5.75M | -4.40%6.11M | -4.40%6.11M | -11.67%5.98M | 46.63%6.7M | 37.92%6.02M | 49.44%6.39M | 49.44%6.39M |
Current accrued expenses | -3.77%12.55M | -1.30%13.15M | -4.08%12.22M | -10.30%15.12M | -10.30%15.12M | -7.83%13.04M | -14.34%13.32M | -23.60%12.74M | -1.81%16.85M | -1.81%16.85M |
Current liabilities | -3.88%18.28M | -7.45%18.53M | -4.19%17.98M | -8.68%21.22M | -8.68%21.22M | -9.08%19.02M | -0.49%20.02M | -10.84%18.76M | 8.41%23.24M | 8.41%23.24M |
Non current liabilities | ||||||||||
Long term debt and capital lease obligation | -10.44%614.94M | -7.98%668.88M | -10.63%671.58M | -9.41%690.02M | -9.41%690.02M | -5.43%686.63M | 16.11%726.86M | 22.16%751.46M | 52.54%761.68M | 52.54%761.68M |
-Long term debt | -10.44%614.94M | -7.98%668.88M | -10.63%671.58M | -9.41%690.02M | -9.41%690.02M | -5.43%686.63M | 16.11%726.86M | 22.16%751.46M | 52.54%761.68M | 52.54%761.68M |
Other non current liabilities | 4.57%9.93M | 8.66%9.91M | 11.51%9.73M | 12.47%9.54M | 12.47%9.54M | 13.35%9.49M | 11.84%9.12M | 8.90%8.72M | 7.13%8.49M | 7.13%8.49M |
Total non current liabilities | -10.24%624.87M | -7.77%678.78M | -10.38%681.31M | -9.17%699.56M | -9.17%699.56M | -5.22%696.12M | -16.48%735.98M | 21.99%760.19M | 51.83%770.16M | 51.83%770.16M |
Total liabilities | -10.07%643.15M | -7.76%697.32M | -10.23%699.28M | -9.15%720.78M | -9.15%720.78M | -5.32%715.14M | -16.13%756M | 20.91%778.95M | 50.07%793.4M | 50.07%793.4M |
Shareholders'equity | ||||||||||
Share capital | 9.98%314.65M | 11.68%303.03M | 19.28%302.05M | 28.48%296.98M | 28.48%296.98M | 29.50%286.1M | 22.95%271.34M | -45.85%253.24M | -50.56%231.14M | -50.56%231.14M |
-common stock | 18.94%7.87M | 15.35%7.28M | 16.96%7.02M | 18.02%6.8M | 18.02%6.8M | 20.00%6.62M | 15.36%6.31M | 12.11%6M | 11.52%5.76M | 11.52%5.76M |
-Preferred stock | 9.77%306.78M | 11.59%295.76M | 19.33%295.04M | 28.75%290.18M | 28.75%290.18M | 29.75%279.48M | 23.15%265.03M | -46.52%247.24M | -51.25%225.38M | -51.25%225.38M |
Retained earnings | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M | 0.00%-25.36M |
Paid-in capital | 36.71%567.18M | 19.14%464.33M | 21.34%438.43M | 26.20%433.11M | 26.20%433.11M | 32.21%414.89M | 19.34%389.74M | 10.39%361.33M | 14.39%343.19M | 14.39%343.19M |
Total stockholders'equity | 26.77%856.46M | 16.72%742M | 21.37%715.12M | 28.37%704.72M | 28.37%704.72M | 32.64%675.62M | 21.81%635.71M | -23.44%589.2M | -26.03%548.96M | -26.03%548.96M |
Noncontrolling interests | -9.46%1.92M | -8.07%1.98M | -6.93%2.04M | -7.08%2.07M | -7.08%2.07M | -2.97%2.12M | --2.16M | --2.19M | --2.23M | --2.23M |
Total equity | 26.65%858.39M | 16.64%743.98M | 21.27%717.16M | 28.23%706.79M | 28.23%706.79M | 32.49%677.75M | 22.22%637.87M | -23.16%591.39M | -25.73%551.2M | -25.73%551.2M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |